Trial Outcomes & Findings for Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant (NCT NCT05899829)

NCT ID: NCT05899829

Last Updated: 2024-12-04

Results Overview

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 42 participants
• Primary outcome timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
• Results posted on: 2024-12-04

Participant Flow

A total of 42 participants were enrolled (20 participants in Part 1 and 22 participants in Part 2) in this study. Only 32 participants (10 participants were never dosed) were dosed into the study to receive either camlipixant + rifampin or camlipixant + rabeprazole creating the Safety Population.

Participant milestones

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 2: Camlipixant 50 mg + Rabeprazole 20 mg Participants received a single oral dose of camlipixant 50 mg tablet on Day 1, followed by repeat oral doses of 20 mg rabeprazole enteric-coated tablets, once daily (QD) from Days 4 to 11, with co-administration of a single oral dose of 50 mg camlipixant tablet with rabeprazole enteric-coated tablet on Day 10. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rabeprazole on Day 4.
Part 1 (Up to Day 22) STARTED	20	0
Part 1 (Up to Day 22) Safety Population	16	0
Part 1 (Up to Day 22) COMPLETED	16	0
Part 1 (Up to Day 22) NOT COMPLETED	4	0
Part 2 (up to Day 21) STARTED	0	22
Part 2 (up to Day 21) Safety Population	0	16
Part 2 (up to Day 21) COMPLETED	0	16
Part 2 (up to Day 21) NOT COMPLETED	0	6

Reasons for withdrawal

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 2: Camlipixant 50 mg + Rabeprazole 20 mg Participants received a single oral dose of camlipixant 50 mg tablet on Day 1, followed by repeat oral doses of 20 mg rabeprazole enteric-coated tablets, once daily (QD) from Days 4 to 11, with co-administration of a single oral dose of 50 mg camlipixant tablet with rabeprazole enteric-coated tablet on Day 10. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rabeprazole on Day 4.
Part 1 (Up to Day 22) Enrolled but did not receive study treatment	4	0
Part 2 (up to Day 21) Enrolled but did not receive study treatment	0	6

Baseline Characteristics

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

Baseline characteristics by cohort

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 2: Camlipixant 50 mg + Rabeprazole 20 mg n=16 Participants Participants received a single oral dose of camlipixant 50 mg tablet on Day 1, followed by repeat oral doses of 20 mg rabeprazole enteric-coated tablets, once daily (QD) from Days 4 to 11, with co-administration of a single oral dose of 50 mg camlipixant tablet with rabeprazole enteric-coated tablet on Day 10. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rabeprazole on Day 4.	Total n=32 Participants Total of all reporting groups
Age, Customized 18 to 55 years	16 Participants n=5 Participants	16 Participants n=7 Participants	32 Participants n=5 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	5 Participants n=7 Participants	6 Participants n=5 Participants
Sex: Female, Male Male	15 Participants n=5 Participants	11 Participants n=7 Participants	26 Participants n=5 Participants
Race/Ethnicity, Customized Others	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
Race/Ethnicity, Customized White	15 Participants n=5 Participants	15 Participants n=7 Participants	30 Participants n=5 Participants

PRIMARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity]) of Camlipixant Day 1	3851.24 Hours*nanograms per milliliter Geometric Coefficient of Variation 39.27	—	—
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity]) of Camlipixant Day 11	1423.84 Hours*nanograms per milliliter Geometric Coefficient of Variation 38.90	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: AUC(0-Infinity) of Camlipixant Day 1	5425.54 Hours*nanograms per milliliter Geometric Coefficient of Variation 29.55	—	—
Part 2: AUC(0-Infinity) of Camlipixant Day 10	5514.74 Hours*nanograms per milliliter Geometric Coefficient of Variation 33.39	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant Day 1	3834.41 Hours*nanograms per milliliter Geometric Coefficient of Variation 39.31	—	—
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant Day 11	1419.39 Hours*nanograms per milliliter Geometric Coefficient of Variation 38.97	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: AUC(0-t) of Camlipixant Day 1	5403.91 Hours*nanograms per milliliter Geometric Coefficient of Variation 29.52	—	—
Part 2: AUC(0-t) of Camlipixant Day 10	5474.24 Hours*nanograms per milliliter Geometric Coefficient of Variation 33.07	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Maximum Observed Concentration (Cmax) of Camlipixant Day 1	819 Nanograms per milliliter Geometric Coefficient of Variation 19.54	—	—
Part 1: Maximum Observed Concentration (Cmax) of Camlipixant Day 11	519 Nanograms per milliliter Geometric Coefficient of Variation 27.84	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Cmax of Camlipixant Day 1	1080 Nanograms per milliliter Geometric Coefficient of Variation 24.74	—	—
Part 2: Cmax of Camlipixant Day 10	912 Nanograms per milliliter Geometric Coefficient of Variation 34.29	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant Day 1	1.000 Hours Interval 0.25 to 2.5	—	—
Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant Day 11	0.750 Hours Interval 0.5 to 3.0	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Tmax of Camlipixant Day 10	1.750 Hours Interval 0.6 to 4.017	—	—
Part 2: Tmax of Camlipixant Day 1	0.750 Hours Interval 0.5 to 1.0	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant Day 1	5.05 Hours Geometric Coefficient of Variation 32.02	—	—
Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant Day 11	1.94 Hours Geometric Coefficient of Variation 28.68	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: T1/2 Following Administration of Camlipixant Day 1	6.01 Hours Geometric Coefficient of Variation 16.90	—	—
Part 2: T1/2 Following Administration of Camlipixant Day 10	6.78 Hours Geometric Coefficient of Variation 17.01	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as [1 - (AUC0-t/AUC0-inf)] * 100.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (% AUC Extrapolation) of Camlipixant Day 1	0.40 Percentage of AUC extrapolation Geometric Coefficient of Variation 45.60	—	—
Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (% AUC Extrapolation) of Camlipixant Day 11	0.30 Percentage of AUC extrapolation Geometric Coefficient of Variation 33.74	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as [1 - (AUC0-t/AUC0-inf)] * 100.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: % AUC Extrapolation of Camlipixant Day 1	0.34 Percentage of AUC extrapolation Geometric Coefficient of Variation 54.00	—	—
Part 2: % AUC Extrapolation of Camlipixant Day 10	0.57 Percentage of AUC extrapolation Geometric Coefficient of Variation 84.03	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Terminal Elimination Rate Constant of Camlipixant Day 1	0.1372 Per hour Geometric Coefficient of Variation 32.02	—	—
Part 1: Terminal Elimination Rate Constant of Camlipixant Day 11	0.3579 Per hour Geometric Coefficient of Variation 28.68	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Terminal Elimination Rate Constant of Camlipixant Day 1	0.1153 Per hour Geometric Coefficient of Variation 16.90	—	—
Part 2: Terminal Elimination Rate Constant of Camlipixant Day 10	0.1022 Per hour Geometric Coefficient of Variation 17.01	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Apparent Clearance (CL/F) of Camlipixant Day 1	12.98 Liters per hour Geometric Coefficient of Variation 39.27	—	—
Part 1: Apparent Clearance (CL/F) of Camlipixant Day 11	35.12 Liters per hour Geometric Coefficient of Variation 38.90	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: CL/F of Camlipixant Day 1	9.22 Liters per hour Geometric Coefficient of Variation 29.55	—	—
Part 2: CL/F of Camlipixant Day 10	9.07 Liters per hour Geometric Coefficient of Variation 33.39	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 11 (Part 1) PK profiles of Camlipixant were adequately characterized, specifically, when administered alone and in combination with Rifampin (Part 1).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Apparent Oral Volume of Distribution (Vz/F) of Camlipixant Day 1	94.66 Liters Geometric Coefficient of Variation 26.40	—	—
Part 1: Apparent Oral Volume of Distribution (Vz/F) of Camlipixant Day 11	98.11 Liters Geometric Coefficient of Variation 29.90	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Population: Pharmacokinetic Parameter Population comprised of all participants for whom the Day 1 and Day 10 (Part 2) PK profiles of Camlipixant, were adequately characterized, specifically, when administered alone and in combination with Rabeprazole (Part 2).

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Vz/F of Camlipixant Day 1	79.96 Liters Geometric Coefficient of Variation 31.72	—	—
Part 2: Vz/F of Camlipixant Day 10	88.74 Liters Geometric Coefficient of Variation 26.78	—	—

SECONDARY outcome

Timeframe: Up to Day 22 for Part1 (Day1 post-dose until Day4 pre-dose of rifampin [Camlipixant 50mg];From Day4 dosing until Day11 pre-dose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study [Day 22] [Camlipixant 50mg+Rifampin 600mg]

Population: Safety population consisted of all participants who received at least one dose of any study drug.

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg n=16 Participants Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg n=16 Participants Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs) TEAEs	3 Participants	14 Participants	2 Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs) TESAEs	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs) TEAEMIs	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg]

Population: Safety population consisted of all participants who received at least one dose of any study drug.

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg n=16 Participants Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg n=16 Participants Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs TESAEs	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs TEAEs	4 Participants	3 Participants	0 Participants
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs TEAEMIs	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 4, Day 11, and Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings Day 4	0 Participants	—	—
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings Day 11	0 Participants	—	—
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings Day 13	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 4, Day 10, and Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings Day 12	0 Participants	—	—
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings Day 4	0 Participants	—	—
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings Day 10	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 11 and Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including diastolic blood pressure (DBP), systolic Blood Pressure (SBP), and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate Day 11	0 Participants	—	—
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate Day 13	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 10 and Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate Day 10	0 Participants	—	—
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate Day 12	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters	2 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international (Intl.) normalized ratio, and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international (Intl.) normalized ratio, and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Outcome measures

Measure	Part 1: Camlipixant 50 mg + Rifampin 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There was a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.	Part 1: Rifampin 600 mg Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11.Participants were followed up for adverse events until end of study (up to Day 22)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis	0 Participants	—	—

Adverse Events

Part 1: Camlipixant 50 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part 1: Rifampin 600 mg

Serious events: 0 serious events

Other events: 14 other events

Deaths: 0 deaths

Part 1: Camlipixant 50 mg+ Rifampin 600 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Part 2: Camlipixant 50 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Part 2 : Rabeprazole 20 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part 2: Camlipixant 50 mg+ Rabeprazole 20 mg

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Measure	Part 1: Camlipixant 50 mg n=16 participants at risk Participants received a single oral dose of 50 mg camlipixant tablet on Day 1.	Part 1: Rifampin 600 mg n=16 participants at risk Participants received repeated oral doses of 2\*300 mg rifampin capsules (total dose 600 mg) once daily on Days 4 to 12.	Part 1: Camlipixant 50 mg+ Rifampin 600 mg n=16 participants at risk Participants received repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. Participants were followed up for adverse events until end of study (up to Day 22)	Part 2: Camlipixant 50 mg n=16 participants at risk Participants received a single oral dose of 50 mg camlipixant tablet on Day 1.	Part 2 : Rabeprazole 20 mg n=16 participants at risk Participants received repeated oral doses of 1\*20 mg rabeprazole enteric-coated tablets once daily on Days 4 to 11.	Part 2: Camlipixant 50 mg+ Rabeprazole 20 mg n=16 participants at risk Participants received repeat oral doses of 20 mg rabeprazole enteric-coated tablets, once daily (QD) from Days 4 to 11, with co-administration of a single oral dose of 50 mg camlipixant tablet with rabeprazole enteric-coated tablet on Day 10. Participants were followed up for adverse events until end of study (up to Day 21).
Nervous system disorders Headache	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Respiratory, thoracic and mediastinal disorders Pharyngeal paraesthesia	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Renal and urinary disorders Chromaturia	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	81.2% 13/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Renal and urinary disorders Pollakiuria	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	12.5% 2/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Renal and urinary disorders Urinary retention	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Gastrointestinal disorders Dry mouth	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Gastrointestinal disorders Abdominal distension	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Gastrointestinal disorders Abdominal pain lower	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Gastrointestinal disorders Constipation	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Gastrointestinal disorders Dyspepsia	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Gastrointestinal disorders Nausea	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
General disorders Chills	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
General disorders Fatigue	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
General disorders Feeling hot	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Musculoskeletal and connective tissue disorders Back pain	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Investigations Alanine aminotransferase increased	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	12.5% 2/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Nervous system disorders Dizziness	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Skin and subcutaneous tissue disorders Seborrhoea	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Psychiatric disorders Insomnia	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Eye disorders Photophobia	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Infections and infestations Nasopharyngitis	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.
Reproductive system and breast disorders Pelvic pain	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	6.2% 1/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.	0.00% 0/16 • Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg] Safety Population comprised of all participants who received at least one dose of any study drug. Adverse events were reported treatment-wise and part-wise.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Email: GSKClinicalSupportHD@gsk.com

Results disclosure agreements

• Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
• Publication restrictions are in place

Restriction type: OTHER